A recent study led by a group of researchers at the University of Texas MD Anderson Cancer Center has found that adding a drug, ribociclib, to hormone therapy significantly increased the overall survival in relatively younger women suffering from advanced breast cancer.
The study covered women who had not yet reached menopause or were still going through it. They were suffering from hormone receptor-positive (HR+) breast cancer and HER2-negative disease. HR+ cancer involves tumours that are receptive to anti-estrogen (endocrine) treatments aimed at blocking hormones while HER2-negative means that the patient lacks a protein of that name. Read More